Sort   by:  
 Page size 
MetabolomicsMetabolic Characteristics of Schisantherin B in Mice with Metabolic-Associated Fatty Liver Disease

Objectives: To observe the pharmacokinetic differences of schisantherin B (STB) in the blood and liver of normal and metabolic-associated fatty liver disease (MAFLD) mice, as well as the changes in CYP450 enzymes in MAFLD mice. Methods: A MAFLD model was established in C57 mice fed with a high-fa...

2025-10-29 | MTBLS13232 | MetaboLights
MetabolomicsAlistipes putredinis Alleviates Metabolic-Associated Fatty Liver Disease via the Acetate-GPR43 Axis by Suppressing Neutrophil ROS Generation

Background & Aims:

Intestinal dysbiosis contributes to the pathogenesis of metabolic-associated fatty liver disease (MAFLD), though precise bacterial targets and mechanisms remain incompletely elucidated. This study investigated whether the depletion of Alistipes putredinis (AP) in adol...

2026-01-16 | MTBLS13699 | MetaboLights
MetabolomicsGenome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is a major risk factor leading to chronic liver disease and type 2 diabetes. Here we chart liver metabolic activity and functionality in NAFLD by integrating global transcriptomic data, from human liver biopsies, and metabolic flux data, measured across the ...
2016-12-15 | MTBLS298 | MetaboLights
MetabolomicsPlatycodin D attenuates alcohol-associated fatty liver disease by suppressing TLR4–NF-κB and activating PPAR signaling

Alcohol-associated fatty liver disease (AFLD) is driven by ethanol-induced metabolic dysregulation and hepatic inflammation, with gut dysbiosis and endotoxin-triggered innate immune activation implicated in disease progression. Platycodin D (PD), a triterpenoid saponin from Platycodon grandifloru...

2026-01-12 | MTBLS13658 | MetaboLights
MetabolomicsAlistipes putredinis Alleviates Metabolic-Associated Fatty Liver Disease via the Acetate-GPR43 Axis by Suppressing Neutrophil ROS Generation

Background & Aims:

Intestinal dysbiosis contributes to the pathogenesis of metabolic-associated fatty liver disease (MAFLD), though precise bacterial targets and mechanisms remain incompletely elucidated. This study investigated whether the depletion of Alistipes putredinis (AP) in adol...

2026-01-15 | MTBLS13694 | MetaboLights
MetabolomicsAlistipes putredinis Alleviates Metabolic-Associated Fatty Liver Disease via the Acetate-GPR43 Axis by Suppressing Neutrophil ROS Generation

Background & Aims:

Intestinal dysbiosis contributes to the pathogenesis of metabolic-associated fatty liver disease (MAFLD), though precise bacterial targets and mechanisms remain incompletely elucidated. This study investigated whether the depletion of Alistipes putredinis (AP) in adol...

2026-01-15 | MTBLS13691 | MetaboLights
MetabolomicsA comprehensive multiomic analysis reveals metabolic reprogramming underlying human Fontan-associated liver disease

BACKGROUND: Single ventricle congenital heart disease (SVCHD) is a severe form of cardiac malformation in which there is only one functional ventricle. The Fontan operation is the current standard of care for SVCHD. Almost all patients who have undergone the Fontan operation develop liver fibrosi...

2024-12-13 | MTBLS10782 | MetaboLights
MetabolomicsLipid Droplet Inhibitors for Disrupting Lipid Accumulation in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Excessive lipid droplet accumulation in hepatocytes drives the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), often leading to inflammation and fibrosis. As obesity and metabolic syndrome rise, MASLD has become a global concern, spurring research into effective trea...
2025-07-17 | MTBLS12359 | MetaboLights
MetabolomicsProtective Effects of Cordycepin against Oxaliplatin-Associated Drug-Induced Fatty Liver Disease and Preliminary Mechanistic Insights

Oxaliplatin (OXA) is a chemotherapeutic agent used to treat multiple malignancies. Although it predominantly causes hepatic sinusoidal obstruction syndrome, it also induces drug-induced fatty liver disease (DIFLD) via lipid metabolic dysregulation and oxidative stress, which persists post-cessati...

2025-09-04 | MTBLS12938 | MetaboLights
MetabolomicsMulti-omic profiles of human nonalcoholic fatty liver disease tissue highlight heterogenic phenotypes
Non-alcoholic fatty liver disease (NAFLD) is a consequence of sedentary life style and high fat diets with an estimated prevalence of about 30% in western countries. It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity. Additionally, polymorphisms in, e.g. APOC3, ...
2015-12-07 | MTBLS174 | MetaboLights
Sort   by:  
 Page size